社交焦虑症3期未达主要终点,Vistagen股价暴跌超80%

Minhua笔记
Dec 18, 2025

12月17日,Vistagen宣布PALISADE-3 III期试验顶线结果,鼻喷剂fasedienol在社交焦虑症(SAD)急性治疗中未达到主要终点(SUDS评分变化无统计学显著差异),与安慰剂组相当。CEO Shawn Singh表示失望,结果与II期及PALISADE-2 III期积极数据不符;公司将全面审查数据,向FDA寻求反馈,并评估对正在进行的PALISADE-4 III期的影响。消息...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10